On Sept. 2, 2025, Emergent BioSolutions announced it had received a $30 million contract modification from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), to supply CYFENDUS^® (Anthrax Vaccine Adsorbed, Adjuvanted). Deliveries were expected to begin in 2025 and were scheduled to be completed by March 2026.

Anthrax is a Tier 1 biological threat due to its potential to be used for a bioterrorist incident and threat to public health and national security. CYFENDUS^® vaccine was approved by the U.S. Food and Drug Administration in July 2023 as a two-dose anthrax vaccine for post-exposure prophylaxis use in individuals 18 through 65 years of age when given with recommended antibacterial drugs.

This follows a previously announced contract modification of $50 million to supply CYFENDUS^® (Anthrax Vaccine Adsorbed, Adjuvanted) in December 2024.

CYFENDUS^® (Anthrax Vaccine Absorbed, Adjuvanted) is a vaccine indicated for post-exposure prophylaxis of anthrax disease following suspected or confirmed exposure to Bacillus anthracis in persons 18 through 65 years of age when given with recommended antibacterial drugs.

The efficacy of CYFENDUS^® vaccine for post-exposure prophylaxis (PEP) is based solely on studies in animal models of inhalational anthrax.